Tech Transfer eNews Blog

Biopharma company licenses drug from George Washington U that combats side effects of cancer treatments


By Jesse Schwartz
Published: January 22nd, 2020

Biopharmaceutical company Hoth Therapeutics has entered into a licensing agreement with George Washington University (GWU) to develop and commercialize a drug that combats the harmful side effects of cancer treatment.

The licensed drug Aprepitant is a Substance P receptor blocker that inhibits neurogenic inflammation side effects that patients suffer from anticancer drugs. Under the agreement, Hoth can negotiate an exclusive patent license, including terms that were pre-negotiated in the parties’ research agreement. The company anticipates finalizing the license this month.

“Our research collaboration with GW has yielded positive preliminary results,” says Robb Knie, CEO of Hoth.

“Our next step will be to plan for the quickest pathway to help patients suffering from adverse events, often so severe that they impair the patient’s compliance with the anticancer treatment and even cause its discontinuation,” Knie adds. “Management looks forward to sharing the preclinical results of our unique formulation of this topical therapeutic upon its completion later this year.”

Source: PR Newswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment